Cue Biopharma (NASDAQ:CUE) Announces Quarterly Earnings Results, Beats Estimates By $2.22 EPS

Cue Biopharma (NASDAQ:CUE) announced its quarterly earnings results on Thursday. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.30) by $2.22, FiscalAI reports. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 101.27%. The firm had revenue of $5.69 million for the quarter, compared to analysts’ expectations of $2.50 million.

Cue Biopharma Stock Down 9.2%

Shares of CUE traded down $2.32 during trading on Friday, reaching $23.01. The company’s stock had a trading volume of 180,065 shares, compared to its average volume of 1,444,925. The company has a market cap of $90.66 million, a price-to-earnings ratio of -4.12 and a beta of 2.37. The company has a fifty day moving average of $226.51 and a two-hundred day moving average of $334.36. Cue Biopharma has a twelve month low of $4.97 and a twelve month high of $41.42.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma during the 3rd quarter valued at approximately $62,000. Stifel Financial Corp lifted its stake in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC raised its holdings in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. 35.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on CUE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cue Biopharma in a research report on Friday, March 27th. Wall Street Zen raised Cue Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.